| Adam H. Schechter |
President & CEO, Director |
$30M |
-$3M |
-9.1% |
Mar 27, 2025 |
| Glenn A. Eisenberg |
Executive Vice President |
$10.7M |
-$6.18M |
-36.7% |
Mar 27, 2025 |
| Brian J. Caveney |
EVP, Pres of ED, CMO & CSO |
$8.46M |
|
|
Mar 27, 2025 |
| Lance Berberian |
EVP, Special Advisor, Strategy |
$4.58M |
-$2.77M |
-37.7% |
Mar 27, 2025 |
| Jean Luc Belingard |
Director |
$4.03M |
|
|
Feb 6, 2024 |
| KerrII B. Anderson |
Director |
$3.66M |
-$919K |
-20.1% |
Mar 5, 2025 |
| Thomas Pike |
Pres & CEO Clinical Business |
$3.57M |
|
|
Jan 9, 2023 |
| Paul R. Kirchgraber |
CEO, Covance Drug Development |
$3.47M |
|
|
May 19, 2023 |
| Peter M. Neupert |
Director |
$3.25M |
|
|
Feb 11, 2025 |
| Garheng Kong |
Director |
$3.24M |
|
|
Feb 11, 2025 |
| Megan D. Bailey |
EVP, Pres, Central Labs & Intl |
$2.66M |
|
|
Apr 1, 2025 |
| Richelle P. Parham |
Director |
$2.45M |
|
|
Feb 11, 2025 |
| Mark S. Schroeder |
EVP, Pres Diagnostics & COO |
$2.27M |
-$1.94M |
-46.1% |
Mar 27, 2025 |
| Dwight Gary Gilliland |
Director |
$2.26M |
-$241K |
-9.66% |
Feb 11, 2025 |
| R. Sanders Williams |
Director |
$1.87M |
|
|
Feb 6, 2024 |
| Jonathan P. DiVincenzo |
EVP, Pres, Central Labs & Intl |
$1.61M |
|
|
Mar 27, 2024 |
| Amy B. Summy |
EVP, Chief Marketing Officer |
$1.56M |
-$1.11M |
-41.5% |
Mar 27, 2025 |
| Sandra D. van der Vaart |
EVP, Chief Legal Officer |
$1.51M |
-$1.45M |
-48.9% |
Mar 27, 2025 |
| Akinbolade Oyegunwa |
Evp, Cio & Cto |
$1.37M |
|
|
Mar 27, 2025 |
| Jeffrey A. Davis |
Director |
$1.29M |
|
|
Feb 11, 2025 |
| Peter J. Wilkinson |
SVP, Chief Accounting Officer |
$1.28M |
-$846K |
-39.8% |
Mar 27, 2025 |
| Judith C. Seltz |
Evp, Chro |
$1.23M |
|
|
Mar 30, 2023 |
| Julia Aijun Wang |
Chief Financial Officer, EVP |
$1.21M |
|
|
Feb 11, 2025 |
| Kathryn E. Wengel |
Director |
$981K |
|
|
Feb 11, 2025 |
| Paul Rothman |
Director |
$813K |
|
|
Feb 11, 2025 |
| Kirsten Marie Kliphouse |
Director |
$753K |
|
|
Feb 11, 2025 |
| Anita Z. Graham |
Evp, Chro |
$697K |
|
|
Feb 11, 2025 |